




Functional adenosine triphosphate-sensitive potassium channel is required in high-carbohydrate diet-induced increase in β -cell mass

Masatoshi Murase¹, Yusuke Seino^{1*} , Ryuya Maekawa¹, Atsushi Iida¹, Kaori Hosokawa¹, Tomohide Hayami^{2,3,4}, Shin Tsunekawa¹, Yoji Hamada¹, Norihide Yokoi² , Susumu Seino², Yoshitaka Hayashi⁵ , Hiroshi Arima¹

¹Departments of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, ²Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, ³Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, ⁴Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, and ⁵Division of Stress Adaptation and Protection, Department of Genetics Research, Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Keywords

β -Cell mass, Adenosine triphosphate-sensitive potassium channel, Carbohydrate

*Correspondence

Yusuke Seino
Tel.: +81-52-744-2142
Fax: +81-52-744-2142
E-mail addresses:
yusuke@med.nagoya-u.ac.jp and
seinoy@fujita-hu.ac.jp

J Diabetes Investig 2019; 10: 238–250

doi:10.1111/jdi.12907

ABSTRACT

Aims/Introduction: A high-carbohydrate diet is known to increase insulin secretion and induce obesity. However, whether or not a high-carbohydrate diet affects β -cell mass (BCM) has been little investigated.

Materials and Methods: Both wild-type (WT) mice and adenosine triphosphate-sensitive potassium channel-deficient (Kir6.2KO) mice were fed normal chow or high-starch (ST) diets for 22 weeks. BCM and the numbers of islets were analyzed by immunohistochemistry, and gene expression levels in islets were investigated by quantitative real-time reverse transcription polymerase chain reaction. MIN6-K8 β -cells were stimulated in solution containing various concentrations of glucose combined with nifedipine and glimepiride, and gene expression was analyzed.

Results: Both WT and Kir6.2KO mice fed ST showed hyperinsulinemia and body weight gain. BCM, the number of islets and the expression levels of *cyclinD2* messenger ribonucleic acid were increased in WT mice fed ST compared with those in WT mice fed normal chow. In contrast, no significant difference in BCM, the number of islets or the expression levels of *cyclinD2* messenger ribonucleic acid were observed between Kir6.2KO mice fed normal chow and those fed ST. Incubation of MIN6-K8 β -cells in high-glucose media or with glimepiride increased *cyclinD2* expression, whereas nifedipine attenuated a high-glucose-induced increase in *cyclinD2* expression.

Conclusions: These results show that a high-starch diet increases BCM in an adenosine triphosphate-sensitive potassium channel-dependent manner, which is mediated through upregulation of *cyclinD2* expression.

INTRODUCTION

Insulin is secreted from pancreatic β -cells and plays an important role in maintaining glucose homeostasis. Pancreatic β -cell mass (BCM) is known to expand to compensate for increase in insulin demand^{1–3}. Indeed, BCM is increased in various rodent models, such as partial pancreatectomy⁴ and pregnancy^{5,6}.

Glucose is transported into the pancreatic β -cells through the glucose transporter and then metabolized to increase the adenosine triphosphate (ATP) concentration in β -cells. The increment of ATP concentration closes the ATP-sensitive potassium (KATP) channels, which consist of the Kir6.2 and sulfonylurea receptor 1 subunits. Closure of KATP channels induces depolarization of the β -cell membrane and allows Ca^{2+} flux through voltage-dependent calcium channels, which induces insulin secretion⁷. It has been reported that

Received 1 March 2018; revised 26 July 2018; accepted 1 August 2018

intravenous glucose infusion for 2–7 days increases BCM in rats^{8,9}. Although proliferation of β -cells and/or acinar cell transdifferentiation into β -cells is considered to be involved in the increase of BCM^{10,11}, whether the KATP channel, which plays an essential role in glucose-induced insulin secretion (GIIS), participates in glucose-induced increase of BCM is not known well. We have previously reported that wild-type (WT) mice fed a high-starch diet (ST), the final product of which is glucose, show body weight gain and higher plasma insulin levels compared with mice fed normal chow (NC) 15 weeks after the intervention of diets despite a mild decrease in insulin sensitivity^{12–14}. In addition, GIIS from isolated islets is enhanced in ST-fed WT mice compared with that in NC-fed WT mice 22 weeks after intervention¹⁴. However, the mechanism of enhanced GIIS in ST-fed WT mice is not elucidated. Although these findings suggest enhancement in the capacity of islets to secrete insulin, BCM and islet function in mice fed ST have not been investigated in detail. In the present study, we investigated BCM in mice fed ST. As BCM was increased in mice fed ST, we further investigated whether GIIS is involved in the increase in BCM. For this purpose, we further analyzed the islets of WT and KATP channel-deficient mice (Kir6.2KO), which showed complete defects in GIIS *in vivo*^{15,16}. The results show that feeding with ST increases BCM due to an increase in the number of islets in a KATP channel-dependent manner.

METHODS

Animal and materials

Kir6.2KO mice were generated as previously described¹⁵. The Kir6.2KO mice had been backcrossed to the C57BL/6J mouse strain for more than five generations, and C57BL/6J (WT) mice were used as the control. Both mice were housed in a room under a standard 12-h light–dark cycle with free access to food and water. Eight-week-old male WT and Kir6.2KO mice were divided into two groups: mice fed NC (carbohydrate consisting of starch 58%, protein 29% and fat consisting of soy oil 13% of total energy) and ST (starch 74%, protein 13%, soy oil 13% of total energy; CLEA Japan, Osaka, Japan)^{12–14} for 22 weeks, and pancreata were excised for analyses at the end-point of the experiment. All animal experiments were carried out according to a protocol approved by the Nagoya University Institutional Animal Care and Use Committee.

Plasma biochemical analyses

Blood glucose levels were measured with Antsense Duo (Horiba, Kyoto, Japan), and plasma insulin levels were measured using a Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Kanagawa, Japan) as previously reported¹⁷.

In Vitro insulin secretion analysis

MIN6-K8 β -cells¹⁸ were incubated for 30 min in Krebs–Ringer buffer containing 2.8 mmol/L glucose, and then stimulated for

240 min by 2.8 mmol/L glucose, 16.7 mmol/L glucose, 16.7 mmol/L glucose plus 10 μ mol/L nifedipine (Wako, Osaka, Japan) or 2.8 mmol/L glucose plus 100 nmol/L glimepiride (Wako). In some experiments, cells were incubated in the presence of an insulin receptor antagonist, S961 (Phoenix Pharmaceuticals, Burlingame, CA, USA), at the concentration of 100 nmol/L throughout the experiments. Released insulin and insulin content were measured by an HTRF Insulin Kit (Cisbio Bioassays, Codolet, France), as previously reported¹⁹.

Insulin content analysis

Insulin content of pancreas or MIN6-K8 β -cells was determined as previously described²⁰. Pancreatic tissue or MIN6-K8 cells were homogenized in Krebs–Ringer buffer (pH 7.4) on ice, and these homogenates were extracted overnight in acid-ethanol (1.5% [v/v] HCl in 75% [v/v] EtOH). Insulin contents in diluted extracts were measured by HTRF Insulin Kit (Cisbio Bioassays). Pancreatic insulin content was corrected by wet tissue weight for analysis.

Isolation of ribonucleic acid and quantitative real-time reverse transcription polymerase chain reaction

Mouse pancreatic islets were isolated using the collagenase digestion method²¹. Total ribonucleic acid (RNA) was collected from isolated islets or MIN6K8 β -cells using the RNeasy Plus Kit (Qiagen, Tokyo, Japan); complementary deoxyribonucleic acid synthesis and quantitative real-time polymerase chain reaction were carried out as previously reported¹². Primer sequences are listed in Table S1. The messenger RNA (mRNA) levels were normalized by those of β -actin mRNA.

Western blot analysis

MIN6-K8 β -cells were stimulated for 20 h by 2.8 mmol/L glucose, 16.7 mmol/L glucose, 16.7 mmol/L glucose plus 10 μ mol/L nifedipine or 2.8 mmol/L glucose plus 100 nmol/L glimepiride. Dispersed MIN6-K8 β -cells were sonicated in lysis buffer (50 mmol/L Tris-HCl [pH 7.5], 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and protease inhibitors [Complete Protease Inhibitor Cocktail; Roche, Basel, Switzerland]). Lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrophoretically transferred onto a polyvinylidene difluoride membrane (Immobilon P; Millipore, Billerica, MA, USA). The membranes were blocked in blocking solution (Tris-buffered saline [20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl] containing 0.1% Tween 20 contained 1% bovine serum albumin) and incubated with primary antibodies against mouse anti-Actin (1:5,000; CP01; CALBIOCHEM, San Diego, CA, USA) or mouse anticyclin D2 (1:500; MA1-12297; Invitrogen, Carlsbad, CA, USA). Immunoreactivity was visualized with an enhanced chemiluminescence system, ECL Prime detecting reagents (GE Healthcare, Little Chalfont, UK) and detected by ImageQuant LAS 4000mini (GE Healthcare).

Immunohistochemistry and morphometric analysis

WT and Kir6.2KO mice were intraperitoneally injected with 5-bromo-2'-deoxyuridine (BrdU; Cosmo Bio Co., Ltd, Tokyo, Japan; 100 mg/kg body weight) 22 weeks after the intervention of the diets, and the whole pancreas was removed 6 h later. The pancreata of WT and Kir6.2KO mice were fixed in 4% paraformaldehyde and then embedded in paraffin. Serial sections of 4- μ m thickness were cut from each paraffin block at 200- μ m intervals and deparaffinized as previously reported²¹. Sections were incubated overnight at 4°C with primary antibodies against insulin (1:300; ab7842; Abcam, Cambridge, MA, USA) or BrdU (1:200; ab6326; Abcam), followed by 90-min incubation in Alexa Fluor-conjugated secondary antibody (1:500; A11074; Alexa Fluor 546; Invitrogen, Grand Island, NY, USA) or (1:500; ab150157; Alexa Fluor 488; Abcam) at room temperature. The total areas of insulin-positive cells (β -cells) and the number of islets in six sections were analyzed using BZ-9000 fluorescent microscope system (Keyence, Osaka, Japan).

Statistical analysis

The results are presented as mean \pm standard error of the mean. Statistical significance was evaluated by ANOVA or Student's *t*-test using GraphPad Prism 7 for Windows (GraphPad Software, La Jolla, CA, USA).

RESULTS

WT mice fed ST showed body weight gain and higher plasma insulin levels

We first investigated body weight, blood glucose levels and plasma insulin levels in WT mice fed NC or ST. A significant difference in body weight was apparent after 12 weeks of feeding and thereafter (Figure 1a). Blood glucose levels and plasma insulin levels under an ad libitum-fed condition were significantly higher in WT mice fed ST 15 weeks after the intervention of the diets compared with those in NC-fed WT mice (Figure 1b,c). Body weight was significantly heavier and blood glucose levels, under an ad libitum-fed condition, were significantly higher in WT mice fed ST compared with those in WT mice fed NC 22 weeks after the intervention of the diets (Figure S1a,b). Pancreatic insulin contents were significantly higher in ST-fed WT compared with those in NC-fed WT 22 weeks after the intervention of the diets (Figure 1d).

Pancreatic islet number and BCM were increased in ST-Fed WT mice 22 weeks after intervention

To address the effect of a high-carbohydrate diet on islets, we next investigated the morphology of islets in WT-fed NC or ST at the end-point of animal experiments, which was 22 weeks after the intervention of the diets. Both BCM and islet number were increased in ST-fed WT mice compared with that in NC-fed WT mice (Figure 2a–c). Mean islet size in ST-fed WT mice was smaller, although not significantly, compared with that in NC-fed WT mice (Figure 2d). We next investigated the

relative number of islets and β -cells area in WT mice. The number of smaller size islets (≤ 200 μ m diameter) was increased in ST-fed WT mice compared with that in NC-fed mice; however, the number of larger size islets (> 200 μ m diameter) was not different between NC-fed and ST-fed WT mice (Figure 2e). To investigate β -cell proliferation, we carried out double staining for BrdU and insulin in the pancreatic sections (Figure 2f, g). The proportion of the double-positive cells was higher, although not significantly, in WT mice fed ST compared with that in WT mice fed NC.

Expression levels of *cyclin D2* mRNA in islets were higher in ST-fed WT mice 22 weeks after intervention

We then analyzed the gene expression levels in islets of NC- and ST-fed WT mice. The expression levels of genes involved in insulin synthesis (*insulin2*), the insulin signal (*Akt1*) and the genes involved in the cell cycle (*cyclinD1*, *D2* and *cyclinE1*) were significantly higher in the islets of ST-fed WT compared with those in the islets of NC-fed WT (Figure 3). In addition, the expression levels of insulin receptor substrate-2 (*Irs2*), which plays an important role in regulation of β -cell proliferation, showed a tendency to increase by ST feeding (Figure 3).

Kir6.2KO mice fed ST also showed hyperinsulinemia and body weight gain

To address whether functional KATP channels and/or GIIS are involved in ST-feeding-induced body weight gain, hyperinsulinemia and increase in BCM, we analyzed Kir6.2KO mice, in which GIIS is completely impaired. Kir6.2KO mice were fed NC or ST for 22 weeks. Body weights in Kir6.2KO mice fed ST were significantly heavier than those in Kir6.2KO mice fed NC after 13 weeks of feeding and thereafter, indicating that ST-induced body weight gain was in a KATP channel-independent manner (Figure 4a). Plasma insulin levels under an ad libitum-fed condition were significantly higher in Kir6.2KO mice fed ST compared with those in NC-fed Kir6.2KO mice 15 weeks after the intervention of the diets, although blood glucose levels were not different between the two groups (Figure 4b,c). Body weight was significantly heavier in Kir6.2KO mice fed ST compared with Kir6.2KO fed NC; however, blood glucose levels, under an ad libitum-fed condition, were not different between Kir6.2KO fed NC and ST 22 weeks after the intervention of the diets (Figure S1c,d). As these data are in parallel with those data in mice 15 weeks after the intervention of diets. Pancreatic insulin contents were not different between NC-fed Kir6.2KO mice and ST-fed Kir6.2KO mice 22 weeks after the intervention of the diets (Figure 4d).

Pancreatic islet number and BCM were not increased in ST-fed Kir6.2KO mice 22 weeks after intervention

We next investigated the morphology of islets in Kir6.2KO mice fed NC and ST. Neither BCM, the total number of islets, mean islet size nor the number of islets (< 100 μ m diameter; from 101 to 200 μ m diameter; and > 200 μ m diameter) was




Figure 1 | Changes in body weight, metabolic parameters and pancreatic insulin content in wild-type (WT) mice. (a) Changes in body weight in mice fed normal chow (NC; white circle; $n = 6$) and a high-starch diet (ST; white triangle; $n = 6$; $*P < 0.05$ compared with NC). (b) Blood glucose and (c) plasma insulin levels under an ad libitum-fed condition. NC-fed mice (white bar; $n = 7$), ST-fed mice (white hatched bar; $n = 8$) 15 weeks after intervention ($*P < 0.05$, $**P < 0.01$). (d) Pancreatic insulin content in mice fed NC (white bar; $n = 13$) or ST (white hatched bar; $n = 9$) 22 weeks after intervention ($**P < 0.01$). Data are expressed as mean \pm standard error of the mean.

different between Kir6.2KO mice fed NC and ST (Figure 5a–e). In addition, the proportion of the BrdU and insulin double-positive cells was not different between the two groups (Figure 5f,g).

Expression levels of *cyclin D2* mRNA in islets were not different between NC-Fed Kir6.2KO mice and ST-Fed Kir6.2KO mice 22 weeks after intervention

We then analyzed the gene expression levels in islets of NC- and ST-fed Kir6.2KO mice. No significant difference in expression levels was observed in genes involved in insulin synthesis, the insulin signal or the cell cycle in Kir6.2KO mice fed ST compared with those fed NC (Figure 6).

KATP channel-dependent pathway plays an important role in the mRNA expression levels of *cyclin D2*, but not of *Irs2*

To address the role of the KATP channel in the regulation of gene expression in β -cells, we analyzed insulin secretion and

gene expression in MIN6-K8 β -cells. Insulin secretion was significantly induced by 16.7 mmol/L glucose or 2.8 mmol/L glucose plus 100 nmol/L glimepiride (a KATP channel inhibitor, sulfonylurea), and GIIS was inhibited by nifedipine (an L-type calcium channel blocker) treatment (Figure 7a). The expression levels of *cyclinD2* and *Irs2* mRNA were increased by 16.7 mmol/L glucose (Figure 7b,c). The increase in *cyclinD2* mRNA expression was completely blocked by nifedipine treatment, whereas that in *Irs2* mRNA expression was marginally affected (Figure 7b,c). In contrast, glimepiride significantly increased the expression levels of *cyclinD2* mRNA, but did not affect the expression levels of *Irs2* mRNA at 2.8 mmol/L glucose concentration (Figure 7b,c), indicating that the KATP channel is involved in the regulation of the expression level of *cyclinD2*, but not *Irs2*. We next examined whether cyclinD2 protein levels are regulated by a KATP channel-dependent pathway. Glucose significantly increased, and glimepiride tended to increase the expression levels of cyclinD2 protein,




Figure 2 | Morphological analysis of islets in wild-type (WT) mice. (a) β -Cell area relative to pancreas area. (b) Number of islets relative to pancreas area. (c) The pancreatic section was stained with the antibody to insulin (red) and 4',6-diamidino-2-phenylindole (blue). Scale bars, 300 μ m. (d) Distribution of islet sizes (* P < 0.05, ** P < 0.01). (e) Mean islet size. (f) The percentage of 5-bromo-2'-deoxyuridine (BrdU)-positive β -cells. (g) The pancreatic section was double stained with the antibody to BrdU (green) and insulin (red) and 4',6-diamidino-2-phenylindole (blue). Scale bars, 100 μ m (n = 6 per each group). Data are expressed as mean \pm standard error of the mean. NC, normal chow; ST, high-starch diet.




Figure 3 | Changes in messenger ribonucleic acid expression levels in islets of wild-type mice. Messenger ribonucleic acid expression levels of the indicated genes in islets isolated from wild-type mice fed normal chow (white bar; $n = 9$) or a high-starch diet (white hatched bar; $n = 13$) for 22 weeks (* $P < 0.05$, ** $P < 0.01$). Data are expressed as mean \pm standard error of the mean.

and the cyclinD2 protein expression levels were decreased, but not significantly, by nifedipine treatment (Figure 7d,e).

To address whether secreted insulin is involved in the regulation of the expression levels of *cyclinD2* or *Irs2*, we pre-treated MIN6-K8 cells with S961, an insulin receptor antagonist, and then stimulated them with 16.7 mmol/L glucose concentration. Pretreatment with S961 did not block GIIS (Figure 7f). S961 also did not block the enhanced expression levels of *cyclinD2* or *Irs2* mRNA by 16.7 mmol/L glucose (Figure 7g,h).

DISCUSSION

In the present study, we showed that mice fed a high-carbohydrate (high starch) diet show increased BCM due to increased islet number. As these changes were not observed in Kir6.2KO mice, our data show that functional KATP channels are required in high-carbohydrate diet-induced increase in BCM.

It has been reported that BCM is reduced in mice deficient in *cyclinD2* or *Irs2*, whereas BCM is increased in transgenic mice overexpressing *Irs2* in a β -cell-specific manner^{22–25}. These

reports show that *cyclinD2* and *Irs2* participate in the regulation of BCM. The expression levels of *cyclinD2* are increased in liver-specific insulin receptor-deficient mice (LIRKO), which display hyperinsulinemia and insulin resistance. However, the increase in BCM is markedly attenuated in *cyclinD2*-deficient liver-specific insulin receptor-deficient mice²⁶. These results also underscore the important role of *cyclinD2* in the increment of BCM under an insulin-resistant state.

Nutrients, such as glucose and fat, regulate β -cell proliferation^{8–10,27–30}. A high-fat diet (HFD) feeding induces body weight gain, hyperglycemia, hyperinsulinemia and increase in BCM within 7 days^{31,32}. An increase in the expression levels of *cyclinD2* and *Irs2* mRNA in islets has been documented in mice fed HFD for 20 weeks²⁴, suggesting that *cyclinD2* and/or *Irs2* contribute to HFD-induced increase in BCM. Furthermore, it has been reported that HFD-induced increase in BCM is attenuated in *Irs2* heterozygous mice²⁴. In the present study, mice fed ST for 22 weeks showed body weight gain and hyperinsulinemia (Figure 1a,c). Additionally, BCM and the




Figure 4 | Changes in body weight, metabolic parameters and pancreatic insulin content in Kir6.2KO mice. (a) Changes in body weight in mice fed normal chow (NC; black circle; $n = 8$) or a high-starch diet (ST; black triangle; $n = 8$; $*P < 0.05$ compared with NC). (b) Blood glucose and plasma insulin levels under an ad libitum-fed condition. NC-fed mice (black bar; $n = 8$) and ST-fed mice (gray hatched bar; $n = 8$) 15 weeks after intervention ($*P < 0.05$). (c) Pancreatic insulin content in mice fed NC (black bar; $n = 7$) or ST (gray hatched bar; $n = 7$) 22 weeks after intervention. Data are expressed as mean \pm standard error of the mean.

expression levels of *cyclinD2* and *Irs2* mRNA are increased in the islets of these mice (Figures 2 and 3). Whether or not the mechanism involved in ST-induced increase in BCM is distinct from that in HFD-induced increase should be further explored in future study. Nevertheless, we have found that the increased BCM in mice fed ST for 22 weeks is due to an increased number of small-to-medium size islets. These results concur with the report that 20% glucose infusion through the jugular vein for 48 h increases the number of smaller size islets in rats.⁹ Accordingly, an increase in the supply of glucose derived from ST might have contributed to the increase in the number of smaller size islets in the present study.

The mechanism involved in glucose-induced β -cell proliferation^{8,9,27,33,34} is not fully explored; however, a number of studies have shown that metabolism of glucose in β -cells, depolarization of the β -cell membrane and increase in intracellular Ca^{2+} concentration is involved^{24,28,35–45}.

Activation of glucokinase (GK), which catalyses the first step of glucose metabolism, increases the expression levels of *cyclinD2* and *Irs2* in rodent islets and insulinoma cell lines^{28,37,42,46}. In human cases with activating mutations of GK, persistent hyperinsulinemic hypoglycemia has been documented, and an increase in islet size has been observed at autopsy^{47,48}. Inhibition of KATP channel function by sulfonylurea has also been shown to induce β -cell proliferation^{41,43}. Sulfonylurea-induced β -cell proliferation is also observed in mice with β -cell-specific GK deficiency. In contrast, activation of the KATP channel by diazoxide suppresses β -cell proliferation induced by GK activation⁴¹. These findings suggest that β -cell proliferation induced by GK activation is dependent on closure of the KATP channel, whereas β -cell proliferation induced by KATP channel closure is independent of GK activation. In the present study, incubation of MIN6-K8




Figure 5 | Morphological analysis of islets in Kir6.2KO mice. (a) β -Cell area relative to pancreas area. (b) Number of islets relative to pancreas area. (c) The pancreatic section was stained with the antibody to insulin (red) and 4',6-diamidino-2-phenylindole (blue). Scale bars, 300 μ m. (d) Distribution of islet sizes. (e) Mean islet size. (f) The percentage of 5-bromo-2'-deoxyuridine (BrdU)-positive β -cells. (g) The pancreatic section was double stained with the antibody to BrdU (green) and insulin (red) and 4',6-diamidino-2-phenylindole (blue). Scale bars, 100 μ m ($n = 6$ per each group). Data are expressed as mean \pm standard error of the mean.




Figure 6 | Changes in messenger ribonucleic acid expression levels in islets from Kir6.2KO mice. Messenger ribonucleic acid expression levels of the indicated genes in islets isolated from Kir6.2KO mice fed normal chow (white bar; $n = 10$) or a high-starch diet (white hatched bar; $n = 12$) for 22 weeks. Data are expressed as mean \pm standard error of the mean.

β -cells in high-glucose media or with sulfonylurea increased *cyclinD2* expression, whereas nifedipine attenuated a high-glucose-induced increase in *cyclinD2* expression. In contrast, expression of *Irs2* was increased by incubation in high-glucose media, but not by sulfonylurea, and a high-glucose-induced increase in *Irs2* expression was not significantly inhibited by nifedipine in MIN6-K8 β -cells. These results are concordant with the report that sulfonylurea does not elevate the expression levels of *Irs2* mRNA in islets of WT mice⁴². Therefore, regulation of *cyclinD2* expression is mediated through the KATP channel, but that of *Irs2* expression is unlikely to be so mediated. These results suggest that closure of the potassium channel is insufficient to induce β -cell proliferation, and that the increase in intracellular Ca^{2+} concentration combined with an increase in the intracellular ATP : adenosine diphosphate ratio produced by glucose metabolism is required for β -cell proliferation^{41,42}.

It has been reported that insulin and downstream insulin signals participate in β -cell proliferation^{49–55}. However, it has

been recently reported that insulin treatment and insulin receptor antagonist S961 do not affect β -cell proliferation in islets of mice¹⁰. In addition, insulin treatment does not increase *cyclinD2* expression levels in MIN6 cells²⁸. Consistent with these reports, S961 was found not to decrease the mRNA expression levels of *cyclinD2* and *Irs2* in MIN6-K8 β -cells under a high-glucose condition in the present study (Figure 7e,f).

Additionally, in the present study, GIIS was not induced during oral glucose tolerance test and intraperitoneal glucose tolerance test in Kir6.2KO mice fed ST (data not shown), as previously reported^{15,16}. Although Kir6.2KO mice are defective in GIIS, plasma insulin levels of Kir6.2KO are increased by ST feeding (Figure 4d). We have previously shown that signals through the vagal nerve regulate insulin secretion in a KATP channel-independent manner⁵⁶, and that such signals might be involved in hyperinsulinemia in Kir6.2KO mice fed ST. The present study has shown that functional KATP channels are required in ST-feeding-induced change in gene expression and increase in BCM, and suggests that a KATP




Figure 7 | Insulin secretion and change in messenger ribonucleic acid expression levels in MIN6-K8 β -cells. (a) Effects of glucose, glimepiride and nifedipine on insulin secretion in MIN6-K8 β -cells. Insulin secretion from MIN6-K8 β -cells was normalized by cellular insulin content ($n = 7$ per group). (b, c) Messenger ribonucleic acid expression levels of *cyclinD2* and *Irs2* in MIN6-K8 β -cells ($n = 9$ per group). (d) Representative immunoblots and (e) relative cyclin D2 protein expression levels normalized with respect to those of actin in MIN6-K8 β -cells ($n = 12$ per group). (f) Effect of S961 on insulin secretion in MIN6-K8 β -cells. Insulin secretion from MIN6-K8 β -cells was normalized by cellular insulin content ($n = 12$ per group). (g, h) Messenger ribonucleic acid expression levels of *cyclinD2* and *Irs2* in MIN6-K8 β -cells ($n = 11$ – 12 ; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$). Data are expressed as means \pm standard error of the mean. CCB, nifedipine; HG, 16.7 mmol/L glucose; LG, 2.8 mmol/L glucose; SU, glimepiride.

channel-independent signal, such as a vagal nerve signal, is insufficient to induce β -cell proliferation.

ACKNOWLEDGMENTS

The authors thank Michiko Yamada and Ryoko Sakamoto (Nagoya University) for technical assistance, and Junichi Miyazaki (Osaka University) for providing MIN6-K8 β -cells. This study was supported by grants from Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science to YS (17k09823), and Suzuken Memorial Foundation to YS.

DISCLOSURE

YS received a scholarship grant from Novo Nordisk Pharma Ltd., MSD K.K., Pfizer, Mitsubishi Tanabe Pharma, Eli Lilly and Company, Novartis Pharma, and Daiichi Sankyo Company Ltd. The other authors declare no conflict of interest.

REFERENCES

- Sachdeva MM, Stoffers DA. Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion. *Mol Endocrinol* 2009; 23: 747–758.
- Hribal ML, Oriente F, Accili D. Mouse models of insulin resistance. *Am J Physiol Endocrinol Metab* 2002; 282: E977–E981.
- Jetton TL, Liang Y, Cincotta AH. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice. *Metabolism* 2001; 50: 1377–1384.
- Peshavaria M, Larmie BL, Lausier J, *et al.* Regulation of pancreatic beta-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. *Diabetes* 2006; 55: 3289–3298.
- Parsons JA, Brelje TC, Sorenson RL. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. *Endocrinology* 1992; 130: 1459–1466.
- Kim H, Toyofuku Y, Lynn FC, *et al.* Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med* 2010; 16: 804–808.
- Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *J Clin Invest* 2011; 121: 2118–2125.
- Bonner-Weir S, Deery D, Leahy JL, *et al.* Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. *Diabetes* 1989; 38: 49–53.
- Jetton TL, Everill B, Lausier J, *et al.* Enhanced beta-cell mass without increased proliferation following chronic mild glucose infusion. *Am J Physiol Endocrinol Metab* 2008; 294: E679–E687.
- Stamateris RE, Sharma RB, Kong Y, *et al.* Glucose induces mouse β -cell proliferation via IRS2, MTOR, and Cyclin D2 but not the insulin receptor. *Diabetes* 2016; 65: 981–995.
- Lipsett M, Finegood DT. Beta-cell neogenesis during prolonged hyperglycemia in rats. *Diabetes* 2002; 51: 1834–1841.
- Maekawa R, Seino Y, Ogata H, *et al.* Chronic high-sucrose diet increases fibroblast growth factor 21 production and energy expenditure in mice. *J Nutr Biochem* 2017; 49: 71–79.
- Niwa Y, Ishikawa K, Ishigami M, *et al.* Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. *Biochem Biophys Res Commun* 2015; 463: 344–350.
- Maekawa R, Ogata H, Murase M, *et al.* Glucose-dependent insulinotropic polypeptide is required for moderate high fat diet, but not high carbohydrate diet-induced weight gain. *Am J Physiol Endocrinol Metab* 2018; 314: E572–E583.
- Miki T, Nagashima K, Tashiro F, *et al.* Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. *Proc Natl Acad Sci USA* 1998; 95: 10402–10406.
- Miki T, Minami K, Shinozaki H, *et al.* Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. *Diabetes* 2005; 54: 1056–1063.
- Ogata H, Seino Y, Harada N, *et al.* KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. *J Endocrinol* 2014; 222: 191–200.
- Iwasaki M, Minami K, Shibasaki T, *et al.* Establishment of new clonal pancreatic β -cell lines (MIN6-K) useful for study of incretin/cyclic adenosine monophosphate signaling. *J Diabetes Investig* 2010; 1: 137–142.
- Seino Y, Ogata H, Maekawa R, *et al.* Fructose induces glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and insulin secretion: role of adenosine triphosphate-sensitive K(+) channels. *J Diabetes Investig* 2015; 6: 522–526.
- Iida A, Seino Y, Fukami A, *et al.* Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. *Diabetologia* 2016; 59: 1533–1541.
- Fukami A, Seino Y, Ozaki N, *et al.* Ectopic expression of GIP in pancreatic β -cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. *Diabetes* 2013; 62: 510–518.
- Withers DJ, Gutierrez JS, Towery H, *et al.* Disruption of IRS-2 causes type 2 diabetes in mice. *Nature* 1998; 391: 900–904.
- Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. *J Clin Invest* 2004; 114: 963–968.
- Terauchi Y, Takamoto I, Kubota N, *et al.* Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. *J Clin Invest* 2007; 117: 246–257.
- Hennige AM, Burks DJ, Ozcan U, *et al.* Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. *J Clin Invest* 2003; 112: 1521–1532.

26. Georgia S, Hinault C, Kawamori D, *et al.* Cyclin D2 is essential for the compensatory beta-cell hyperplastic response to insulin resistance in rodents. *Diabetes* 2010; 59: 987–996.
27. Alonso LC, Yokoe T, Zhang P, *et al.* Glucose infusion in mice: a new model to induce beta-cell replication. *Diabetes* 2007; 56: 1792–1801.
28. Salpeter SJ, Klochendler A, Weinberg-Corem N, *et al.* Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β -cells through glycolysis and calcium channels. *Endocrinology* 2011; 152: 2589–2598.
29. Moullé VS, Vivot K, Tremblay C, *et al.* Glucose and fatty acids synergistically and reversibly promote beta cell proliferation in rats. *Diabetologia* 2017; 60: 879–888.
30. Pascoe J, Hollern D, Stamateris R, *et al.* Free fatty acids block glucose-induced β -cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. *Diabetes* 2012; 61: 632–641.
31. Stamateris RE, Sharma RB, Hollern DA, *et al.* Adaptive β -cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression. *Am J Physiol Endocrinol Metab* 2013; 305: E149–E159.
32. Tajima K, Shirakawa J, Okuyama T, *et al.* Effects of metformin on compensatory pancreatic β -cell hyperplasia in mice fed a high-fat diet. *Am J Physiol Endocrinol Metab* 2017; 313: E367–E380.
33. Levitt HE, Cyphert TJ, Pascoe JL, *et al.* Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. *Diabetologia* 2011; 54: 572–582.
34. Metukuri MR, Zhang P, Basantani MK, *et al.* ChREBP mediates glucose-stimulated pancreatic β -cell proliferation. *Diabetes* 2012; 61: 2004–2015.
35. Lingohr MK, Briaud I, Dickson LM, *et al.* Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells. *J Biol Chem* 2006; 281: 15884–15892.
36. Demozay D, Tsunekawa S, Briaud I, *et al.* Specific glucose-induced control of insulin receptor substrate-2 expression is mediated via Ca^{2+} -dependent calcineurin/NFAT signaling in primary pancreatic islet β -cells. *Diabetes* 2011; 60: 2892–2902.
37. Shirakawa J, Togashi Y, Sakamoto E, *et al.* Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic β -cells. *Diabetes* 2013; 62: 3448–3458.
38. Heit JJ, Apelqvist AA, Gu X, *et al.* Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. *Nature* 2006; 443: 345–349.
39. Srinivasan S, Bernal-Mizrachi E, Ohsugi M, *et al.* Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. *Am J Physiol Endocrinol Metab* 2002; 283: E784–E793.
40. Wang W, Walker JR, Wang X, *et al.* Identification of small-molecule inducers of pancreatic beta-cell expansion. *Proc Natl Acad Sci USA* 2009; 106: 1427–1432.
41. Porat S, Weinberg-Corem N, Tornovsky-Babaey S, *et al.* Control of pancreatic β cell regeneration by glucose metabolism. *Cell Metab* 2011; 13: 440–449.
42. Nakamura A, Togashi Y, Orime K, *et al.* Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions. *Diabetologia* 2012; 55: 1745–1754.
43. Guiot Y, Henquin JC, Rahier J. Effects of glibenclamide on pancreatic beta-cell proliferation in vivo. *Eur J Pharmacol* 1994; 261: 157–161.
44. Namkung Y, Skrypnik N, Jeong MJ, *et al.* Requirement for the L-type Ca^{2+} channel $\alpha(1D)$ subunit in postnatal pancreatic beta cell generation. *J Clin Invest* 2001; 108: 1015–1022.
45. Futamura M, Yao J, Li X, *et al.* Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. *Diabetologia* 2012; 55: 1071–1080.
46. Wei P, Shi M, Barnum S, *et al.* Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. *Diabetologia* 2009; 52: 2142–2150.
47. Kassem S, Bhandari S, Rodríguez-Bada P, *et al.* Large islets, beta-cell proliferation, and a glucokinase mutation. *N Engl J Med* 2010; 362: 1348–1350.
48. Cuesta-Muñoz AL, Huopio H, Otonkoski T, *et al.* Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. *Diabetes* 2004; 53: 2164–2168.
49. Kulkarni RN, Brüning JC, Winnay JN, *et al.* Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell* 1999; 96: 329–339.
50. Otani K, Kulkarni RN, Baldwin AC, *et al.* Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in *beta1RKO* mice. *Am J Physiol Endocrinol Metab* 2004; 286: E41–E49.
51. Ueki K, Okada T, Hu J, *et al.* Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. *Nat Genet* 2006; 38: 583–588.
52. Okada T, Liew CW, Hu J, *et al.* Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. *Proc Natl Acad Sci USA* 2007; 104: 8977–8982.
53. Hashimoto N, Kido Y, Uchida T, *et al.* Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. *Nat Genet* 2006; 38: 589–593.
54. Tuttle RL, Gill NS, Pugh W, *et al.* Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKB α . *Nat Med* 2001; 7: 1133–1137.

55. Bernal-Mizrachi E, Wen W, Stahlhut S, *et al.* Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. *J Clin Invest* 2001; 108: 1631–1638.
56. Seino Y, Miki T, Fujimoto W, *et al.* Cephalic phase insulin secretion is KATP channel independent. *J Endocrinol* 2013; 218: 25–33.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1 | Body weight and blood glucose levels in mice under an ad libitum-fed condition.

Table S1 | Primers used for quantitative real-time polymerase chain reaction.